Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers

(2012) Yazdi K. Pithavala et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

(2011) B. I. Rini et al.   CLINICAL CANCER RESEARCH

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

(2011) J. Fruehauf et al.   CLINICAL CANCER RESEARCH

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

(2011) Yoshihiko Tomita et al.   EUROPEAN JOURNAL OF CANCER

A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers

(2011) Y. Chen et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Effective Global Drug Development Strategy for Obtaining Regulatory Approval in Japan in the Context of Ethnicity-Related Drug Response Factors

(2010) K Ichimaru et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

(2010) Yazdi K. Pithavala et al.   INVESTIGATIONAL NEW DRUGS

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

(2010) Michael A. Tortorici et al.   INVESTIGATIONAL NEW DRUGS

Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

(2009) Radojka M. Savic et al.   AAPS Journal

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

(2009) Y. K. Pithavala et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

(2009) Brett E. Houk et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients

(2009) Toru Mukohara et al.   CANCER SCIENCE

Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

(2009) M. L. Maitland et al.   CLINICAL CANCER RESEARCH

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

(2009) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study

(2009) Joan H. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

(2009) Ronan J. Kelly et al.   Targeted Oncology

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis

(2008) Xiaolei Zhu et al.   ACTA ONCOLOGICA

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

(2008) M. Scartozzi et al.   ANNALS OF ONCOLOGY

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

(2008) Shenhong Wu et al.   LANCET ONCOLOGY

Home Blood-Pressure Monitoring in Patients Receiving Sunitinib

(2008) Michel Azizi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

(2007) J.-J. Mourad et al.   ANNALS OF ONCOLOGY